Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.

Intellia Therapeutics ( (NTLA) ) just unveiled an announcement.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top ...

“This enables the model to predict how small DNA changes affect an organism’s fitness, generate realistic genome-length ...

genXtraits Inc. has announced that it has entered into an agreement with Pairwise to deploy its Fulcrum editing tools to ...

This study presents important findings on cold tolerance shared between hibernating and non-hibernating mammals, identifying a key molecule, GPX4, through multi-species genome-wide CRISPR screens. The ...

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...

But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...

In one of the most close­ly-watched are­nas in biotech, In­tel­lia says its gene edit­ing treat­ment for a heart mus­cle ...

The recent updates from the Phase 1 trials of NTLA-2001, an in-vivo CRISPR/Cas9 based therapy, have shown encouraging results in ATTR-CM and ATTR-PN conditions. These findings, presented at the ...

It is driven by developments in personalised medicine, gene therapy, and CRISPR technology. The global regenerative medicine ...

We recently compiled a list of the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2024. In this article, we are going to ...